It's concluded that EAM-2201 has the prospective to bring about in vivo pharmacokinetic drug interactions when co-administered with substrates of CYP2C8, CYP3A4 and UGT1A3, and is particularly evaluated in pooled human liver microsomes. EAM-2201 was incubated with human hepatocytes for three h inside a CO2 incubator as well as metabolites https://terryt616fuj0.newbigblog.com/profile